The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Aug 27

PMID 34445237

Citations 17

Authors

Grzegorz Grzesk

Daniel Rogowicz

Lukasz Wolowiec

Agnieszka Ratajczak

Wojciech Gilewski

Malgorzata Chudzinska

Anna Sinkiewicz

Joanna Banach

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases are the most common cause of death in the world. For almost 60 years, vitamin K antagonists (VKAs) were the mainstay of anticoagulation therapy, but in recent years direct oral anticoagulants (DOACs) have become the anticoagulant treatment of choice. DOACs were initially considered drugs with no significant food interactions; however, clinical observations from daily practice have proved otherwise as interactions with food ingredients have been reported. Food, dietary supplements or herbs may contain substances that, when administered concomitantly with DOACs, can potentially affect the plasma concentration of the drugs. The aim of this paper was to evaluate the clinical significance of drug-food interactions of DOACs, such as dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban. Patients treated with anticoagulants should avoid products containing and take special care with other food ingredients. As the interest in dietary supplements is on the rise, healthcare providers can contribute to the development of well-designed clinical trials on interactions between DOACs and food, and distribute sufficient knowledge about the proper use of these supplements among patients.

Citing Articles

Why patients fail to seek information on OTC product interactions with a direct-acting oral anticoagulant: perspectives on information-seeking.

Magee M, Schwartz J, McArthur A, Liu R, Tarn D BMC Prim Care. 2025; 26(1):47.

PMID: 39984862 PMC: 11846430. DOI: 10.1186/s12875-025-02740-1.

Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran.

Yang Z, Tan W, Li Q, Wang Y, Liu S, Chen L Front Pharmacol. 2024; 15:1454612.

PMID: 39619611 PMC: 11605329. DOI: 10.3389/fphar.2024.1454612.

Modulation of Multispecific Transporters by Extract and Its Major Phytoconstituents.

Szilvasy N, Lajer P, Horvath A, Veres K, Hohmann J, Schelz Z Pharmaceutics. 2024; 16(11).

PMID: 39598486 PMC: 11597817. DOI: 10.3390/pharmaceutics16111363.

Use of Direct Anticoagulants in Kidney Transplant Recipients: Review of the Current Evidence and Emerging Perspectives.

Afsar B, Afsar R, Caliskan Y, Lentine K Am J Cardiovasc Drugs. 2024; 25(2):135-146.

PMID: 39476316 DOI: 10.1007/s40256-024-00692-y.

Knowledge, Attitudes, and Awareness of Food and Drug Interactions (FDI) Among Nurses on General Medical Wards: A Cross-Sectional Study.

Elajez R, Alkhawaja R, Kehyayan V, Shukaili K, Swallmeh E SAGE Open Nurs. 2024; 10:23779608241280847.

PMID: 39411707 PMC: 11475285. DOI: 10.1177/23779608241280847.

References

Stangier J, Rathgen K, Stahle H, Gansser D, Roth W . The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64(3):292-303. PMC: 2000643. DOI: 10.1111/j.1365-2125.2007.02899.x. View

Chatterjee P, Franklin M . Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003; 31(11):1391-7. DOI: 10.1124/dmd.31.11.1391. View

Adeboyeje G, Sylwestrzak G, Barron J, White J, Rosenberg A, Abarca J . Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017; 23(9):968-978. PMC: 10398327. DOI: 10.18553/jmcp.2017.23.9.968. View

Auxtero M, Chalante S, Abade M, Jorge R, Fernandes A . Potential Herb-Drug Interactions in the Management of Age-Related Cognitive Dysfunction. Pharmaceutics. 2021; 13(1). PMC: 7835864. DOI: 10.3390/pharmaceutics13010124. View

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A . Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018; 135:60-79. DOI: 10.1016/j.phrs.2018.07.016. View

Marx W, McKavanagh D, McCarthy A, Bird R, Ried K, Chan A . The Effect of Ginger (Zingiber officinale) on Platelet Aggregation: A Systematic Literature Review. PLoS One. 2015; 10(10):e0141119. PMC: 4619316. DOI: 10.1371/journal.pone.0141119. View

Zhang W, Lim L . Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos. 2008; 36(7):1283-90. DOI: 10.1124/dmd.107.019737. View

10.

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

11.

Chudzinska M, Rogowicz D, Wolowiec L, Banach J, Sielski S, Bujak R . Resveratrol and cardiovascular system-the unfulfilled hopes. Ir J Med Sci. 2020; 190(3):981-986. DOI: 10.1007/s11845-020-02441-x. View

12.

Hajda J, Rentsch K, Gubler C, Steinert H, Stieger B, Fattinger K . Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci. 2010; 41(5):729-35. DOI: 10.1016/j.ejps.2010.09.016. View

13.

Mendell J, Noveck R, Shi M . Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol. 2012; 60(4):335-41. DOI: 10.1097/FJC.0b013e31826265b6.. View

14.

Mueck W, Schwers S, Stampfuss J . Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013; 11(1):10. PMC: 3726366. DOI: 10.1186/1477-9560-11-10. View

15.

Levy I, Attias S, Ben Arye E, Goldstein L, Schiff E . Interactions between dietary supplements in hospitalized patients. Intern Emerg Med. 2016; 11(7):917-27. DOI: 10.1007/s11739-015-1385-3. View

16.

Corsini A, Ferri N, Proietti M, Boriani G . Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs. 2020; 80(11):1065-1083. DOI: 10.1007/s40265-020-01328-6. View

17.

Grzesk G, Wozniak-Wisniewska A, Blazejewski J, Gorny B, Wolowiec L, Rogowicz D . The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications. Int J Mol Sci. 2021; 22(1). PMC: 7795697. DOI: 10.3390/ijms22010282. View

18.

Wilkinson G . Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352(21):2211-21. DOI: 10.1056/NEJMra032424. View

19.

Martin K, Lee C, Farrell T, Moll S . Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. Am J Med. 2017; 130(5):517-524. PMC: 5401640. DOI: 10.1016/j.amjmed.2016.12.033. View

20.

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View